- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Companion Cell.
Displaying page 1 of 2.
EudraCT Number: 2010-023343-16 | Sponsor Protocol Number: CC-4047-MM-003/C | Start Date*: 2011-03-31 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: Open-label, multi-center, single-arm study for the safety and efficacy of pomalidomide (CC-4047) monotherapy for subjects with refractory or relapsed and refractory multiple myeloma: a companion st... | |||||||||||||
Medical condition: Refractory or relapsed and refractory multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) GR (Completed) IT (Completed) CZ (Completed) NL (Completed) SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005758-36 | Sponsor Protocol Number: UTX-TGR-304 | Start Date*: 2016-10-28 | |||||||||||
Sponsor Name:TG Therapeutics | |||||||||||||
Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005014-34 | Sponsor Protocol Number: CLGX818A2202 | Start Date*: 2014-05-15 | ||||||||||||||||
Sponsor Name:NOVARTIS FARMA S.p.A. | ||||||||||||||||||
Full Title: A phase II, single arm, open-label, multicenter, study of oral LGX818 in patients with BRAF V600 mutant advanced non-small cell lung cancer that have progressed during or after at least one prior c... | ||||||||||||||||||
Medical condition: Non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005060-15 | Sponsor Protocol Number: EMR100070-004 | Start Date*: 2015-06-23 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) DE (Prematurely Ended) GB (Completed) BE (Completed) HU (Completed) DK (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) CZ (Completed) PL (Completed) HR (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006293-72 | Sponsor Protocol Number: GS-US-312-0117 | Start Date*: 2012-05-08 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS 1101) for Previously Treated Chronic Lymphocytic Leukemia A C... | |||||||||||||
Medical condition: Chronic lymphocytic leukemia (CLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005586-75 | Sponsor Protocol Number: CSET2014/2204_PIPSeN | Start Date*: 2015-10-08 | ||||||||||||||||
Sponsor Name:Gustave Roussy | ||||||||||||||||||
Full Title: A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer | ||||||||||||||||||
Medical condition: Advanced non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002102-30 | Sponsor Protocol Number: CC-5013-MM-012 | Start Date*: 2005-02-17 | |||||||||||
Sponsor Name:CELGENE EUROPE LIMITED | |||||||||||||
Full Title: OPEN-LABEL, SINGLE-ARM STUDY OF THE SAFETY AND EFFICACY OF CC-5013 MONOTHERAPY FOR SUBJECTS WITH MULTIPLE MYELOMA A COMPANION STUDY FOR STUDIES THAL-MM-003, CC-5013-MM-009, AND CC-5013-MM-010 | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012152-24 | Sponsor Protocol Number: ABT4710n | Start Date*: 2011-10-24 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A PHASE II, MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF THE SAFETY, EFFICACY AND PHARMACOKINETICS OF ABT-263 IN COMBINATION WITH DOSE-INTENSIVE RITUXIMAB, OR DOSE-INTENSIVE RITUXIMAB A... | |||||||||||||
Medical condition: B Cell Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005765-23 | Sponsor Protocol Number: ESR-14-10083 | Start Date*: 2017-10-10 |
Sponsor Name:VU Medical Centre | ||
Full Title: Companion biomarker development for MEDI4736 treated non-small-cell lung cancer patients using 89Zirconium-labeled MEDI4736 – a feasibility study | ||
Medical condition: Stadium IV non-small-cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003126-25 | Sponsor Protocol Number: DZ2019E0001 | Start Date*: 2022-02-14 | |||||||||||
Sponsor Name:Dizal (Jiangsu) Pharmaceutical Co., Ltd | |||||||||||||
Full Title: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001578-31 | Sponsor Protocol Number: CINC280A2301 | Start Date*: 2020-08-26 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advance... | |||||||||||||
Medical condition: cMET mutated NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) DE (Completed) PT (Completed) FR (Completed) LT (Completed) BE (Completed) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001456-34 | Sponsor Protocol Number: CTMX-M-2029-001 | Start Date*: 2019-01-17 | |||||||||||||||||||||||||||||||
Sponsor Name:CytomX Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas | |||||||||||||||||||||||||||||||||
Medical condition: Metastatic or locally advanced unresectable solid tumor or diffuse large B-cell lymphoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015507-52 | Sponsor Protocol Number: CLBH589D2308 | Start Date*: 2009-11-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | |||||||||||||
Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003315-35 | Sponsor Protocol Number: B7461006 | Start Date*: 2017-08-01 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc, | |||||||||||||||||||||||
Full Title: A Phase 3, randomized, open-label study of lorlatinib (PF-06463922) monotherapy versus crizotinib monotherapy in the first-line treatment of patients with advanced ALK-positive non-small cell lung ... | |||||||||||||||||||||||
Medical condition: Advanced ALK positive non small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) DK (Prematurely Ended) CZ (Ongoing) BE (Ongoing) NL (Ongoing) PL (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001982-26 | Sponsor Protocol Number: OZM-063 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:The Hospital for Sick Children | |||||||||||||
Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma... | |||||||||||||
Medical condition: Unresectable or progressive low grade glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000589-39 | Sponsor Protocol Number: ADP-0044-002 | Start Date*: 2020-02-13 | |||||||||||||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||||||||||||
Full Title: A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
Medical condition: Advanced Synovial Sarcoma Myxoid/Round Cell Liposarcoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003967-23 | Sponsor Protocol Number: PCYC-1115-CA | Start Date*: 2013-02-05 | |||||||||||
Sponsor Name:Pharmacyclics, Incorporated | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic L... | |||||||||||||
Medical condition: Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000076-28 | Sponsor Protocol Number: BO29554 | Start Date*: 2017-08-25 | ||||||||||||||||
Sponsor Name:Roche Farma S.A (Soc.Unipersonal) que realiza el ensayo | ||||||||||||||||||
Full Title: A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORIN... | ||||||||||||||||||
Medical condition: Advanced or metastatic Non-small cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) PL (Ongoing) BE (Ongoing) DE (Completed) FR (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002425-52 | Sponsor Protocol Number: H3E-MC-JMEN(a) | Start Date*: 2005-03-24 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer | |||||||||||||
Medical condition: Non Small Cell Lung Cancer Stage IIIB or Stage IV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000603-91 | Sponsor Protocol Number: CA013-004 | Start Date*: 2016-08-30 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid Tumors | |||||||||||||
Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.